Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.

Kasper Bonnesen Uffe Heide-Jørgensen Diana Hedevang ChristensenTimothy L LashSean Hennessy Anthony A Matthews Lars Pedersen Reimar Wernich Thomsen Morten Schmidt

Published in: Circulation (2024)

Empagliflozin and dapagliflozin initiators had no differences in 6-year cardiovascular outcomes in adults with treated type 2 diabetes with or without coexisting atherosclerotic cardiovascular disease or HF.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
randomized controlled trial
insulin resistance
study protocol
systematic review
clinical trial
phase iii
cardiovascular events
heart failure
cardiovascular risk factors
metabolic syndrome
coronary artery disease
weight loss